GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech companies, including stem cell play ReNeuron and immunotherapeutics specialist Autolus. Most notably, Berriman was Chairman of Heptares Therapeutics, another company exclusively focused on GPCR drug development. Berriman’s insight and experience in the GPCR space will no doubt be most valuable to Confo.

TiGenix will issue 55 million new shares at the current share price, accounting for a capital injection of 50 million euros.

The cooperation between Pfizer and IBM concerning Watson, an artificial intelligence system, was announced on the Forbes Healthcare Summit following a pilot project during the past year and a half.